Skip to content
graphic from Breaking Barriers summary that shows why covid-19 and HIV remain prevalent in U.S. communities of color - structural racism pathways are: income, homelessness, unemployment, residental segregation, insurance-healthcare access, incarceration, provider bias, federal laws, and local policies

TAG and COVID-19 Prevention Network Fact Sheets

  • Dorrit Walsh

These three fact sheets were developed by TAG in partnership with the COVID-19 Prevention Network (CoVPN) and the Black AIDS Institute (BAI), and they aim to foster community understanding of COVID-19 vaccine research and development, as well as highlight community perspectives on the topic.

Read more

Delivering on the Promise of Long-Acting Technologies

  • Dorrit Walsh

By Susan Swindells* and Mark Harrington This issue of TAGline explores the exciting opportunities and challenges that come with the development of long-acting formulations for the prevention and treatment of infectious diseases. For many years to date, patients and providers…

Read more

Community Engagement on TB through Storytelling

  • Dorrit Walsh

Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. These storyboards follow three individuals journeys through diagnosis, treatment and care, and the barriers they face.

Read more

Unique Barriers to COVID-19 Vaccine Access for Black Communities

  • Dorrit Walsh

On Wednesday, May 19, 2021,Treatment Action Group (TAG), Black AIDS Institute, (BAI), and the COVID Prevention Trials Network (CoVPN) will convene a virtual news conference and roundtable discussion to disseminate findings from a soon-to-be published report: Breaking Barriers: Surveying Community Perspectives on COVID-19 Vaccine Research.

Read more

Civil Society Letter to Donors, Countries, and Health Actors to Improve Access to GeneXpert and Other Diagnostics

  • Dorrit Walsh

TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for diagnostics as a global norm; and increasing investments in alternative rapid molecular tests to promote competition and improve access.

Read more
Back To Top